IMMUNOCORE HLDGS ADS/1 (6YG) - Total Liabilities
Based on the latest financial reports, IMMUNOCORE HLDGS ADS/1 (6YG) has total liabilities worth €686.24 Million EUR (≈ $802.28 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
IMMUNOCORE HLDGS ADS/1 - Total Liabilities Trend (2022–2025)
This chart illustrates how IMMUNOCORE HLDGS ADS/1's total liabilities have evolved over time, based on quarterly financial data. See 6YG current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
IMMUNOCORE HLDGS ADS/1 Competitors by Total Liabilities
The table below lists competitors of IMMUNOCORE HLDGS ADS/1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $138.49 Million |
|
Sally Beauty Holdings Inc
NYSE:SBH
|
USA | $2.03 Billion |
|
Shaily Engineering Plastics Limited
NSE:SHAILY
|
India | Rs4.30 Billion |
|
Jadard Technology Inc. A
SHG:688252
|
China | CN¥454.01 Million |
|
Titagarh Rail Systems Limited
NSE:TITAGARH
|
India | Rs12.61 Billion |
|
PT Sarana Menara
JK:TOWR
|
Indonesia | Rp57.73 Trillion |
|
CTS Corporation
NYSE:CTS
|
USA | $242.72 Million |
|
Shenzhen Urban Transport Planning Center Co. Ltd.
SHE:301091
|
China | CN¥975.06 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down IMMUNOCORE HLDGS ADS/1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is IMMUNOCORE HLDGS ADS/1 worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.80 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how IMMUNOCORE HLDGS ADS/1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for IMMUNOCORE HLDGS ADS/1 (2022–2025)
The table below shows the annual total liabilities of IMMUNOCORE HLDGS ADS/1 from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €686.24 Million ≈ $802.28 Million |
+5.77% |
| 2024-12-31 | €648.79 Million ≈ $758.50 Million |
+184.36% |
| 2023-12-31 | €228.16 Million ≈ $266.74 Million |
+21.45% |
| 2022-12-31 | €187.86 Million ≈ $219.63 Million |
-- |
About IMMUNOCORE HLDGS ADS/1
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebe… Read more